American Cryostem Corp (fka CRYO)

[thetinman]

news out on CRYO https://finance.yahoo.com/news/american-cryostem-issues-shareholder-letter-123000886.html

American CryoStem Issues Shareholder Update Letter
ACCESSWIRE ACCESSWIRE•August 4, 2020
EATONTOWN, NJ / ACCESSWIRE / August 4, 2020 / American CryoStem Corporation (OTC PINK:CRYO) (the "Company"), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, is pleased to issue the following shareholder update letter from Chief Executive Officer John Arnone.


Dear American CryoStem family, partners and shareholders,

I write to you today with gratitude, pride and excitement. Gratitude and pride for the dedication and support of our employees, partners and shareholders in our accomplishments to date, and great excitement for the value I see for us in the path ahead.

With our main 4 core patents (collect-process-store-return to point of care) granted we are now entering the exciting commercialization phase. Timing has coincided with two specific areas of unmet medical needs; the global COVID-19 pandemic and Traumatic Brain Injury (TBI), which are particularly a point of focus for the U.S. military, the Veterans Administration and the National Football League (NFL).

Our pipeline of opportunities is at its highest in Company history. As cellular therapy becomes front and center as a potential treatment modality for COVID-19, there is robust interest in our proprietary autologous adult stem cell platform as the potential for reinfection grows and the virus mutates and spreads.

Our Company is well-positioned in Regenerative and Personalized medicine. Our patented adult stem cell ‘end-to-end' platform for thecollection, processing, transportation, storage and return to point-of-care is well suited for successive personalized treatments relating to COVID-19 and the long-term health effects associated with the virusidentified as "Post Viral Syndrome",

Our business/economic model is multi-pronged and encompasses a domestic network of over 125 physicians in 38 states and a growing global footprint of licensed facilities operating on our cellular platform..

In the U.S., we are receiving institutional interest inour cellular therapy platform in response to the COVID-19 pandemic and regenerative therapies are being investigated for limiting the damage caused by the virus.

Another area of focus in the U.S., and potentially internationally, is our use of stem cells in addressing the unmet need for Post-Concussion Syndrome (PCS). There are over 10 million concussions worldwide annually,occurring every 15 seconds. In the U.S., approximately 30% of overseas deployed military sustain head trauma. Head trama is a major systemic medical problem confronting the military for which therapeutic solutions are being sought. The NFL Concussion Settlement Program Fund committed $2 billion over 65 years to seek treatment modalities to ameliorate collateral effects of concussions and Traumatic Brain Injury (TBI).

We have developed an autologous therapy treatment focused on alleviating and/or ameliorating neurological, cognitive and functional effects of Post Concussion Syndrome (PCS) and complications related toTBI (Traumatic Brain Injury). Currently, there are no FDA approved drugs or cellular therapies available designed to treat the inflammatory responses or repair the physical damage to the brain. Our focus is to provide the opportunity to mitigate life altering damage caused by such head trauma and related conditions to improve patient health, quality of life and well-being.

Continue reading